DOW JONES23,433.57+779.71 3.44%
S&P 5002,749.98+90.57 3.41%
NASDAQ8,090.90+203.64 2.58%

Wedbush Initiates Coverage On Beam Therapeutics with Outperform Rating, Announces $32 Price Target

Wedbush analyst David Nierengarten initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Outperform rating and a $32 price target.

Benzinga · 03/02/2020 14:54

Wedbush analyst David Nierengarten initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Outperform rating and a $32 price target.